Contact l Sitemap

home industries issues reasearch weblog press

Home  » Industries » Pharmaceuticals

News Articles : Displaying 6-25 of 161


SWITZERLAND: Davos Scales Back Glitz
by Associated PressNew York Times
January 25th, 2009
The economic crisis that emerged out the collapse of securities based on shaky U.S. mortgages poses challenges for the Davos World Economic Forum, an arena that has championed market-driven approaches.

US: Research Center Tied to Drug Company
by GARDINER HARRISThe New York Times
November 24th, 2008
Court documents reveal that Dr. Joseph Biederman, a renowned child psychiatrist, pushed Johnson & Johnson to fund a research center whose goal was “to move forward the commercial goals of J&J.”

US: Radio Host Has Drug Company Ties
by GARDINER HARRISThe New York Times
November 21st, 2008
An influential psychiatrist who was the host of the popular NPR program “The Infinite Mind” earned at least $1.3 million from 2000 to 2007 giving marketing lectures for drugmakers, income not mentioned on the program.

US: Eli Lilly settles Zyprexa inquiries in 32 states
by TOM MURPHY and MARLEY SEAMANAssociated Press
October 7th, 2008
Drugmaker Eli Lilly & Co. cleared another legal cloud hanging over its top-selling drug Zyprexa when it announced a $62 million settlement Tuesday, but several other storms are still brewing for the antipsychotic medication.

ARGENTINA: Is GlaxoSmithKline Behaving Badly in Argentina?
by AINA HUNTERABC News
September 23rd, 2008
Michaela, a deceased 5 month old, is one of more than 13,000 Argentine children to participate in a clinical study implemented a little more than a year ago by the London-based GlaxoSmithKline, the world's second-largest drug manufacturer.

US: Judge to Unseal Documents on the Eli Lilly Drug Zyprexa
by MARY WILLIAMS WALSHThe New York Times
September 5th, 2008
A federal judge in Brooklyn decided on Friday to unseal confidential materials about Eli Lilly’s top-selling antipsychotic drug Zyprexa, citing “the health of hundreds of thousands of people” and “fundamental questions” about the way drugs are approved for new uses.

US: U.S. Drug Ads Questioned
by KEITH J. WINSTEIN and SUZANNE VRANICAThe Wall Street Journal
September 3rd, 2008
Consumer advertising for prescription drugs had a negligible impact on sales of products studied by Harvard Medical School researchers -- in a finding that may confound both advertisers and their opponents.

US: For Widely Used Drug, Question of Usefulness Is Still Lingering
by ALEX BERENSONThe New York Times
September 1st, 2008
About the only point on which both sides agree is that no one can judge ezetimibe’s safety and benefits for certain without more data, ideally from a clinical trial covering more than 10,000 patients and lasting several years, long enough to show that the drug actually helps patients live longer or avoid heart attacks.

GLOBAL: Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise
by Elisabeth RosenthalThe New York Times
August 19th, 2008
The lightning-fast transition from newly minted vaccine to must-have injection in the United States and Europe represents a triumph of what the manufacturers call education and their critics call marketing.

US: Psychiatric Group Faces Scrutiny Over Drug Industry Ties
by BENEDICT CAREY and GARDINER HARRISThe New York Times
July 12th, 2008
Senator Charles E. Grassley, right, Republican of Iowa, is demanding that the American Psychiatric Association give an accounting of its financing from the pharmaceutical industry.

US: U.S. Probe of Glaxo's Paxil Widens
by ALICIA MUNDYThe Wall Street Journal
June 20th, 2008
A Justice Department investigation of GlaxoSmithKline PLC's handling of its blockbuster antidepressant drug Paxil, including its marketing and safety research, appears to be widening.

US: Mannatech Settles Holder Suits
by SUZANNE SATALINEWall Street Journal
June 13th, 2008
Dietary-supplements maker Mannatech Inc. said it settled several lawsuits with shareholders who accused the company of using improper sales tactics to boost the value of the stock.

US: Researchers Fail to Reveal Full Drug Pay
by GARDINER HARRIS and BENEDICT CAREYThe New York Times
June 8th, 2008
A world-renowned Harvard child psychiatrist whose work has helped fuel an explosion in the use of powerful antipsychotic medicines in children earned at least $1.6 million in consulting fees from drug makers from 2000 to 2007 but for years did not report much of this income to university officials, according to information given Congressional investigators.

US: Walgreen to Pay $35 Million To Settle Drug-Switch Charges
by HEATHER WON TESORIEROWall Street Journal
June 4th, 2008
Walgreen Co. has agreed to pay $35 million to settle allegations that it improperly switched customers to more expensive forms of pills paid for by Medicaid, the government health care program for the poor.

US: Merck Agrees to Settlement Over Vioxx Ads
by THE ASSOCIATED PRESSThe New York Times
May 21st, 2008
The drug maker, Merck & Company, has agreed to pay $58 million as part of a multistate settlement of accusations that its ads for the once-popular painkiller Vioxx deceptively played down the health risks.

US: Merck Wrote Drug Studies for Doctors
by STEPHANIE SAULThe New York Times
April 16th, 2008
The drug maker Merck drafted dozens of research studies for a best-selling drug, then lined up prestigious doctors to put their names on the reports before publication, according to an article to be published Wednesday in a leading medical journal.

US: Drug Companies to Reveal Grant Practices
by THE ASSOCIATED PRESSThe New York Times
April 11th, 2008
Watchdog groups say the companies are trying to derail legislation that would require public disclosure of their giving.

US: Drug Makers Near Old Goal: A Legal Shield
by GARDINER HARRIS and ALEX BERENSONThe New York Times
April 6th, 2008
The Bush administration has argued strongly in favor of the doctrine, which holds that the F.D.A. is the only agency with enough expertise to regulate drug makers and that its decisions should not be second-guessed by courts. The Supreme Court is to rule on a case next term that could make pre-emption a legal standard for drug cases. The court already ruled in February that many suits against the makers of medical devices like pacemakers are pre-empted.

US: Eli Lilly E-Mail Discussed Unapproved Use of Drug
by ALEX BERENSONThe New York Times
March 17th, 2008
John C. Lechleiter, an Eli Lilly official who is about to become the company's top executive, wrote an e-mail message in 2003 that appears to have encouraged Lilly to promote its schizophrenia medicine Zyprexa for a use not approved by federal drug regulators.

US: In Trial, Alaska Says Lilly Concealed Risks of a Schizophrenia Drug
by ALEX BERENSONThe New York Times
March 6th, 2008
Eli Lilly, the drug maker, systematically hid the risks and side effects of Zyprexa, its best-selling schizophrenia medicine, a lawyer for the State of Alaska said Wednesday in opening arguments in a lawsuit that contends the drug caused many schizophrenic patients to develop diabetes.